| Status | 即將出版Forthcoming |
| Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy | |
| Chen, Guihua1,2,3; Xiong, Wei1,2,3; Gu, Zeyun2,4; Gao, Yanrong2; Hou, Jiazhen5; Long, Li1,2,3; Wang, Huiyuan2; Asrorov, Akmal M.2,6; Muhitdinov, Bahtiyor2,6; Xu, Qin1; Huang, Yongzhuo2,3,5 | |
| 2022-12-31 | |
| Source Publication | International Journal of Biological Macromolecules
 |
| ISSN | 0141-8130 |
| Volume | 223Pages:1485-1494 |
| Abstract | The development of cancer vaccines based on tumor-associated antigens is hurdled by lack of an efficient adjuvant and insufficient efficacy. To improve the efficacy of vaccines, a genetically-engineered method was employed in this work to achieve the codelivery of antigen and adjuvant to enhance immune responses. Trichosanthin is a plant-derived protein that possesses cancer immune stimulation function. A genetically engineered protein vaccine composed of trichosanthin (adjuvant) and legumain domain (a peptidic antigen) was constructed, which was further chemically modified with mannose for targeting dendritic cells (DCs). The method is facile and ready for scaling up for massive production. Such a “two-in-one” vaccine is advantageous for codelivery for augmenting the immune responses. The vaccine inhibited the tumors by triggering a robust cytotoxic T lymphocyte response in the orthotopic-breast-tumor mice. Furthermore, the vaccine was loaded into the temperature-sensitive hydrogel based on Pluronic F127 for implanting use in the post-surgical site. The sustained-released vaccine from the hydrogel inhibited not only the tumor recurrence but also the lung metastases of breast cancer. These findings demonstrated that it was a safe and effective vaccination for breast cancer immunotherapy in a prophylactical and therapeutical manner for remodeling the tumor immune microenvironment and arresting tumor growth. |
| Keyword | Cancer vaccine Engineered protein Hydrogel Legumain Post-surgery Trichosanthin |
| DOI | 10.1016/j.ijbiomac.2022.11.045 |
| URL | View the original |
| Language | 英語English |
| Scopus ID | 2-s2.0-85142194312 |
| Fulltext Access | |
| Citation statistics | |
| Document Type | Journal article |
| Collection | University of Macau |
| Affiliation | 1.Artemisinin Research Center, Guangzhou University of Chinese Medicine, Guangzhou, 12 Jichang Road, 510450, China 2.State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 501 Haike Rd, 201203, China 3.Zhongshan Institute for Drug Discovery, The Institutes of Drug Discovery and Development, CAS, Zhongshan, 528437, China 4.State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Taipa, Avenida Wai Long, Macau SAR, China 5.School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing, 138 Xianlin Avenue, 10, 210023, China 6.Institute of Bioorganic Chemistry, Uzbekistan Academy of Sciences, Tashkent, 83, M. Ulughbek Street, 100125, Uzbekistan |
| Recommended Citation GB/T 7714 | Chen, Guihua,Xiong, Wei,Gu, Zeyun,et al. Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy[J]. International Journal of Biological Macromolecules, 2022, 223, 1485-1494. |
| APA | Chen, Guihua., Xiong, Wei., Gu, Zeyun., Gao, Yanrong., Hou, Jiazhen., Long, Li., Wang, Huiyuan., Asrorov, Akmal M.., Muhitdinov, Bahtiyor., Xu, Qin., & Huang, Yongzhuo (2022). Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy. International Journal of Biological Macromolecules, 223, 1485-1494. |
| MLA | Chen, Guihua,et al."Mannosylated engineered trichosanthin-legumain protein vaccine hydrogel for breast cancer immunotherapy".International Journal of Biological Macromolecules 223(2022):1485-1494. |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment